Clinical trials of drugs in development for neurological disorders presented in Denver April 18, 2002
Orally active VEGFR tyrosine kinase inhibitor RWJ-417975 exerts antitumor activity in mouse models April 18, 2002
Novel VTA from Oxigene markedly reduces tumor blood flow and exerts potent antitumor effects April 17, 2002
Late-breaking AACR presentation describes preclinical profile of new orally active mTOR inhibitor April 17, 2002
RSS